Sigachi Industries Limited has inaugurated a new research and development center in Hyderabad aimed at strengthening its pharmaceutical capabilities. The facility is focused on advancing active pharmaceutical ingredient (API) development and expanding analytical functions to meet evolving regulatory requirements.
With a planned investment of up to USD 1 million, the center is expected to support the development of select priority APIs and complex intermediates. It also aligns Sigachi’s pharma portfolio with key therapeutic segments to enhance operational focus. The center will be staffed by a dedicated research team tasked with developing products for global markets.
Amit Raj Sinha, Managing Director and CEO of Sigachi Industries Limited, said, “This R&D Center is a strategic asset that will significantly strengthen our development capabilities and enable us to respond swiftly to market needs, it reflects our focus on building operational depth and creating long-term value for our customers, partners, and stakeholders in an evolving global pharmaceutical environment.”
